Trial reportSeminars in thoracic and cardiovascular surgery2018
Tissue-engineered Vascular Grafts in Children With Congenital Heart Disease: Intermediate Term Follow-up.
Trial report in Seminars in thoracic and cardiovascular surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 99 citations in OpenAlex.
- Small Diameter Vascular Grafts Made in Minutes.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Physiological Response of Tissue-Engineered Vascular Grafts to Vasoactive Agents in an Ovine Model.Tissue engineering. Part C, Methods · 2025Article
- Tissue Engineered Vascular Grafts: A Quarter Century Journey of Courage, Challenge, and Persistence.JACC. Basic to translational science · 2025Article
- Constrained optimization of scaffold behavior for improving tissue engineered vascular grafts.Journal of biomechanics · 2025Article
- Small-diameter artery grafts engineered from pluripotent stem cells maintain 100% patency in an allogeneic rhesus macaque model.Cell reports. Medicine · 2025Article
- Current clinical and translational challenges in temporomandibular joint reconstruction.Frontiers in bioengineering and biotechnology · 2025Review
- Construction of vascular grafts based on tissue-engineered scaffolds.Materials today. Bio · 2024Review
- Off-the-Shelf Synthetic Biodegradable Grafts Transform In Situ into a Living Arteriovenous Fistula in a Large Animal Model.Advanced healthcare materials · 2024Article
- Vascular Damage and Repair - Are Small-Diameter Vascular Grafts Still the "Holy Grail" of Tissue Engineering?Physiological research · 2024Review
- Functionalization ofBioactive materials · 2023Article
- Cells and Materials for Cardiac Repair and Regeneration.Journal of clinical medicine · 2023Review
- Tissue Engineering of Vascular Grafts: A Case Report From Bench to Bedside and Back.Arteriosclerosis, thrombosis, and vascular biology · 2023Review
- The Application of Porous Scaffolds for Cardiovascular Tissues.Bioengineering (Basel, Switzerland) · 2023Review
- Artificial Scaffolds in Cardiac Tissue Engineering.Life (Basel, Switzerland) · 2022Review
- Vascular Remodeling of Clinically Used Patches and Decellularized Pericardial Matrices Recellularized with Autologous or Allogeneic Cells in a Porcine Carotid Artery Model.International journal of molecular sciences · 2022Article
- Vascular implants - new aspects for in situ tissue engineering.Engineering in life sciences · 2022Review
- Tissue engineering: Relevance to neonatal congenital heart disease.Seminars in fetal & neonatal medicine · 2022Review
- Strategies to counteract adverse remodeling of vascular graft: A 3D view of current graft innovations.Frontiers in bioengineering and biotechnology · 2022Review
- The path to a hemocompatible cardiovascular implant: Advances and challenges of current endothelialization strategies.Frontiers in cardiovascular medicine · 2022Review
- Complications and management of functional single ventricle patients with Fontan circulation: From surgeon's point of view.Frontiers in cardiovascular medicine · 2022Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Tissue engineering holds great promise for the advancement of cardiovascular surgery as well as other medical fields. Tissue-engineered vascular grafts have the ability to grow and remodel and could therefore make great advances for pediatric cardiovascular surgery. In 2001, we began a human clinical trial evaluating these grafts in patients with a univentricular physiology. Herein, we report the long-term results of patients who underwent implantation of tissue-engineered vascular grafts as extracardiac total cavopulmonary conduits. Tissue-engineered vascular grafts seeded with autologous bone marrow mononuclear cells were implanted in 25 patients with univentricular physiology. The graft is composed of a woven fabric of poly-l-lactide acid or polyglycolic acid and a 50:50 poly (l-lactic-co-ε-caprolactone) copolymer. Patients were followed up with postoperatively in a multidisciplinary clinic. Median patient age at operation was 5.5 years and the mean follow-up period was 11.1 years. There was no graft-related mortality during the follow-up period. There was also no evidence of aneurysmal formation, graft rupture, graft infection, or calcification. Seven (28%) patients had asymptomatic graft stenosis and underwent successful balloon angioplasty. Stenosis is the primary complication of the tissue-engineered vascular graft. Avoidance of anticoagulation therapy would improve patients' quality of life. Tissue-engineered vascular grafts have feasibility in pediatric cardiovascular surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.